Karriereverlauf von Marc E. Uknis
Ehemalige bekannte Positionen von Marc E. Uknis
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| GEMI THER | Technik-/Wissenschafts-/F&E-Leiter | 01.03.2020 | 11.04.2021 |
| ACHILLION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.01.2018 | 28.01.2020 |
Ausbildung von Marc E. Uknis
| George Washington University | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 4 |
Operativ
| Corporate Officer/Principal | 1 |
| Masters Business Admin | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Achillion Pharmaceuticals, Inc.
 Achillion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Achillion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of oral small molecule complement system inhibitors. Its pipeline includes Danicopan and ACH-5228. The company was founded on August 17, 1998 and is headquartered in Blue Bell, PA. | Health Technology |
Gemini Therapeutics, Inc.
 Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Börse
- Insiders
- Marc E. Uknis
- Erfahrung
